Novo Nordisk
Main (gene editing) focus: Gene therapies and gene editing for the treatment of genetic blood diseases
Company stage: Commercial
Diseases (gene editing): Haemophilia and other severe genetic diseases
Genome editing tool: megaTAL
Funding stage: Public (NASDAQ:NOVO)
Location: Bagsvaerd, Denmark
Website: https://www.novonordisk.dk/
Pipeline: https://www.novonordisk.com/science-and-technology/r-d-pipeline.html
Gene editing partnerships: bluebird bio, SNIPR Biome
Novo Nordisk is a big pharma company, developing therapies within the areas of diabetes, obesity, cardiovascular diseases, blood diseases and liver diseases. The company is mainly involved in the gene-editing space through its partnership with bluebird bio. These two companies have agreed to jointly develop next generation in vivo genome-editing treatments for genetic diseases including haemophilia, using bluebird's proprietary megaTAL gene-editing technology. Novo Nordisk also has a collaboration with microbiome-focused Danish company SNIPR Biome.